SCHEMBL6482789

SCHEMBL6482789

CNC(=O)[C@H]1O[C@@H](n2cnc3c(NC)nc(Cl)nc32)[C@H](O)[C@@H]1N

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 18/20 0.83
ADORA1 P30542 4/20 0.73
ADORA2B P29275 1/20 0.67
MAPK1 P28482 2/20 0.60
NPC1 O15118 1/20 0.60
GMNN O75496 1/20 0.60
ALDH1A1 P00352 1/20 0.60
LMNA P02545 1/20 0.60
MAPT P10636 1/20 0.60
THRB P10828 1/20 0.60
HPGD P15428 1/20 0.60
BLM P54132 1/20 0.60
PMP22 Q01453 1/20 0.60
KMT2A Q03164 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
TP53 P04637 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
PKM P14618 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29762306 0.85 ADORA3 (0.89) ADORA3ADORA1ADORA2BMAPK1NPC1
SCHEMBL6481597 0.85 ADORA3 (1.00) ADORA3ADORA1ADORA2BALDH1A1LMNA
SCHEMBL6493751 0.83 ADORA3 (0.68) ADORA3ADORA1ADORA2BMAPK1NPC1
SCHEMBL6482676 0.80 ADORA3 (0.80) ADORA3ADORA1MAPK1NPC1GMNN
SCHEMBL12935992 0.79 ADORA3 (0.79) ADORA3ADORA1ADORA2BADORA2A
SCHEMBL6210936 0.77 ADORA3 (0.84) ADORA3ADORA1ADORA2BMAPK1NPC1
SCHEMBL12935990 0.76 ADORA3 (0.74) ADORA3ADORA1ADORA2BADORA2A
SCHEMBL4134920 0.76 ADORA1 (0.77) ADORA3ADORA1ADORA2BMAPK1LMNA
SCHEMBL1994057 0.76 ADORA1 (0.77) ADORA3ADORA1ADORA2BMAPK1LMNA
SCHEMBL1994061 0.76 ADORA1 (0.77) ADORA3ADORA1ADORA2BMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050176700-A1 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases ACTELION PHARMACEUTICALS LTD. (CH) 2005-08-11 US claimed
US-20050171049-A1 Compounds for the treatment of ischemia DENINNO MICHAEL P (US) 2005-08-04 US claimed
US-20030055021-A1 Compounds for the treatment of ischemia PFIZER, INC. 2003-03-20 US claimed
EP-1241176-A1 Purine derivatives for the treatment of ischemia Pfizer Products Inc. (US) 2002-09-18 EP claimed
US-20050171049-A1 Compounds for the treatment of ischemia DENINNO MICHAEL P (US) 2005-08-04 US disclosed
US-20030055021-A1 Compounds for the treatment of ischemia PFIZER, INC. 2003-03-20 US disclosed
EP-1241176-A1 Purine derivatives for the treatment of ischemia Pfizer Products Inc. (US) 2002-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171049-A1 Compounds for the treatment of ischemia TNNI3, ADRB3, TBXA2R ADORA3 4/4885ADORA1 14/4885ADORA2B 5/4885
US-20030055021-A1 Compounds for the treatment of ischemia TNNI3, ADRB3, FABP3 ADORA3 29/4885ADORA1 89/4885ADORA2B 85/4885
US-20050176700-A1 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases REN, AGTR1, ACE ADORA3 1353/4885ADORA1 1799/4885ADORA2B 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.